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Abstract
Over the last years, a Europe-wide trend toward a patient-focused approach is develop-
ing and is influencing the decision-making process related to the clinical research. This 
new vision aims to draw on patient knowledge and experience in order to deliver ben-
efits for all stakeholders of the drug development process, optimizing the clinical study 
design. In this context, the “patient empowerment” concept has been developed as an 
approach encouraging the active participation and self-determination of the patients in 
the caring procedure. For this reason, in 2016, European Patients’ Academy (EUPATI) 
launched a public consultation that ended in September 2016 with the release of the 
EUPATI guidance for patient involvement in the medicine research and development 
process. Likewise, the recommendations on the “Summaries of Clinical Trial Results 
for Laypersons” for the Implementation of Regulation (EU) No 536/2014 recommended 
a clear and comprehensible communication of the clinical trial results to the patients. 
However, rarely, all these attempts for the patient involvement pay attention to the pedi-
atric population needs. An innovative approach for the patients’ involvement in pediatric 
clinical research is represented by the Young Persons Advisory Groups, an organization 
composed of youths, patients, and carers, actively participating in clinical research and 
advising researchers and their teams.
Keywords: patient empowerment, patient involvement, patient-centered approach, 
child-friendly approach, age-tailored information, patient advocacy, YPAGs—Young 
Persons Advisory Groups
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1. Introduction: patient empowerment and involvement
In 1998, the World Health Organization (WHO) released the second edition of the WHO 
Health Promotion Glossary, where, for the first time, the concept of “Empowerment of the 
health” was described [1]. WHO defines empowerment as “a process through which people 
gain greater control over decisions and actions affecting their health.” In addition, the docu-
ment makes a difference between community or individual empowerment according to the 
involvement of individuals acting for themselves or collectively to influence social, economic, 
and physical conditions impacting their health and quality of life. The WHO Glossary goes 
on underling that this process, which can be social, cultural, psychological, or political, allows 
individual or social groups to shed light on what are their needs making clearer what are the 
efforts required to achieve their goals in life. In this context, the WHO definition also includes 
a description of health promotion as the process able to create the favorable conditions to con-
vert efforts of individuals and groups into health outcomes as described above [1].
Actually, the concept of empowerment is somewhat complex and includes several psycho-
logical and social components that, over the last years, have been studied empirically. In par-
ticular, Peter Schulz and Kent Nakamoto underlined the need to distinguish and separate the 
concepts of empowerment and high health literacy. They are often mismatched, but it is nec-
essary to recognize that they are conceptually and empirically distinct. High literacy, in fact, 
does not necessarily entail empowerment and vice versa. Furthermore, in order to be sure that 
the empowerment process is successful, it is important to have both a high literacy and a high 
degree of mastery. At the same time, the impacts of health literacy and patient empowerment 
are deeply intertwined, considering that the prevalence of one of them could bring to nonop-
timal health outcomes: high levels of health literacy without an adequate degree of patient 
empowerment can make the patient too dependent on health professionals; while, on the 
contrary, high degree of empowerment may bring to unsafe health choices if not associated 
with an appropriate level of health literacy (Figure 1).
Finally, the achievement of empowerment by the patient depends on some personal abilities 
as well as the environmental conditions. In fact, some life skills of the patient, such as the scien-
tific approach and the wisdom, are fundamental to acquire the proper knowledge to interact 
with their healthcare provider. On the other hand, it is essential that the external environment 
stimulates the patient propensity to be an active protagonist of the healthcare process. The 
Figure 1. Relationship between empowerment and health literacy.
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healthcare provider should encourage the patients to participate in the care process, avoiding 
that the patient acts as a passive user.
Overall, four components have been identified as being fundamental to the process of patient 
empowerment: (1) acquisition by patients of sufficient knowledge to be able to engage with 
their healthcare provider, (2) patient skills, (3) the presence of a facilitating environment, and 
(4) understanding by the patient of his/her role.
The transition from empowerment to patient involvement implies an important change of 
attitude: healthcare actors are no longer giving patients their information and allowing them 
to control the outcomes, but rather they are now actively working to engage patients in their 
healthcare. In particular, patient participation refers to the involvement of the patient in deci-
sion-making or expressing opinions about different treatment methods, which includes shar-
ing information, feelings, and signs, and accepting health team instructions. As a result, the 
focus has gone from a patient-driven process to a healthcare provider-driven one.
Generally, several studies and European initiatives carried out over the last years have 
revealed that such patient-centered approach may raise the adequacy of exams and care and 
reduce the risk of litigation and expenses [2].
2. Patient empowerment: a new frontier in the European scenario
2.1. The European Patients’ Academy on therapeutic innovation (EUPATI)
In Europe, the patient-focus approach is becoming a key point in the decision-making pro-
cess related to the clinical research and an important element of pharma companies’ business 
models and research ethics committees who advocate for the protection of patients in clinical 
trials. It requires new strategies, new organizational structures, and a culture change across 
the pharma sector as well as a direct link with patient experts who are capable of providing 
advice on the value of treatments and on what health outcomes are relevant to patients.
Over the last years, in fact, several initiatives have been carried out with the scope to sensi-
tize the clinical world and encourage the patient involvement in the clinical research. One 
of the most significant initiatives is the European Patients’ Academy (EUPATI) [3], funded 
within “Call 3″ of the Innovative Medicines Initiative (IMI) in the period from February 2012 
to January 2017, with the scope to prompt a major reflection on the importance of the patient 
involvement in the medicines development process. EUPATI is a Paneuropean project imple-
mented as a public-private partnership by a collaborative multistakeholder consortium from 
the pharmaceutical industry, academia, not-for-profit, and patient organizations. Its main 
activities include the education and training on medicines development, clinical trials, medi-
cines regulations, and health technology assessment, to increase the capacity of patients to 
understand and contribute to medicines research and development and even improve the 
availability of objective, reliable, patient-friendly information for the public. For this purpose, 
EUPATI provides several tools for the patients training such as the toolbox medicine devel-
opment and English language patient expert training courses. EUPATI’s interest in raising 
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awareness of the clinical world on the patient empowerment has led to the launch of a public 
consultation, which ended in September 2016 with the release of the EUPATI guidance for 
patient involvement in the medicines research and development process [4]. Each guidance 
suggests an area where at present there are opportunities for patient involvement, and in 
particular:
• industry-led medicines R&D,
• ethical review of clinical trials,
• regulatory processes,
• health technology assessment (HTA).
The necessity to have a clear guidance on patient involvement in different areas of the medicines 
development process originates from some needs and lacks in the clinical research, such as:
• existing code of trial conduct does not describe the involvement of the patients,
• patients and patients’ organizations should be involved proactively during early discov-
ery, development, and postapproval stages and not only in the clinical development,
• overarching guidance on meaningful and ethical interaction is missing.
For these reasons, the guidance is devoted to provide recommendations for all stakeholders 
aiming to interact with patients, for example by delivering a clear and complete definition of 
“patient” (patients, carers/family representatives, expert patient advocates, etc.), establishing 
the operating procedures for a long-term interaction and explaining the key elements of a 
written collaboration agreement.
In particular, the guidance provides the following definitions:
• “Individual patients” are persons whose main contribution is represented by their per-
sonal experience of a disease or treatment regardless of whether they may or may not have 
specific knowledge in the medicine research and development process.
• With personal experience of living with a disease, they may or may not have technical 
knowledge in “Carers” who are paid or volunteer persons helping “individual patients.”
• “Patient advocates” are persons who have knowledge and competences to gather patients 
living with a specific disease and to support them regardless if they may or may not be af-
filiated with an organization.
• “Patient organization representatives” are persons within a patient organization on a spe-
cific disease or issue, who have been designated to represent the point of view of the orga-
nization itself.
• “Patient experts” are patients with experience of living with a specific disease that, differ-
ently from “individual patients,” have also specific knowledge in research and development 
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(R&D) and/or regulatory affairs achieved through training activities such as courses pro-
vided by EUPATI on the full spectrum of medicines R&D.
All these procedures are aimed to draw on patient knowledge and experience and under-
stand what it is like to live with a specific condition, how care is administered, and the day-
to-day use of the medicines. As a result, they allow to incorporate patient needs and priorities 
in an optimized drug development process as well as to achieve a constructive dialog with 
the patient and a functional exchange of information, fundamental to speed up a successful 
clinical process.
2.2. Summaries of clinical trial results for laypersons
On April 16, 2014, the European Parliament and the Council of the European Union (EU) 
released the Regulation EU No 536/2014 [5] on clinical trials on medicinal products for human 
use, to ensure that the rules for conducting clinical trials are identical through the EU. The aim 
of the Clinical Trial Regulation is to favor the conduction of the clinical trials in accordance 
with the highest standards of patient safety for all the EU Member States. These goals are 
achieved through some harmonized procedures for authorization, specific sponsor obliga-
tions, and simplified reporting procedures. Furthermore, such regulation foresees a section 
dedicated to communication of the results to patients. In particular, the article 37 requires 
sponsors to provide summary results of clinical trials in the EU Portal and Database in a for-
mat understandable to laypersons and the Annex V of the regulation outlines 10 elements that 
must be considered in the lay summary writing.
In this context, from June 1, 2016 to August 31, 2016, the Directorate General for Health and 
Food Safety, DG SANTE launched a public consultation on the “Summary of Clinical Trial 
Results for Laypersons,” developed by the expert group on clinical trials, in order to collect 
comments and suggestions by all the stakeholders involved in clinical research to implement 
the Clinical Trials Regulation (EU) No 536/2014. The main objective of this document is to 
provide recommendations and templates for the production of a summary of clinical trial 
results for laypersons by sponsors and investigators, in accordance with Annex V of the EU 
Clinical Trials Regulation. Despite not mandatory, this document intends to make the sum-
maries more accessible to the lay persons.
The recommendations of the clinical trials expert group on the “Summaries of Clinical 
Trial Results for Laypersons” [6], which have been published on January 2017 in EudraLex 
Volume 10, Chapter V, provide the following principles:
• develop the summary for a general public audience and do not assume any prior knowl-
edge of the trial,
• develop the layout and content for each section in terms of style, language, and literacy 
level to meet the needs of the general public,
• keep the document as short as possible,
• focus on unambiguous, factual information,
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• ensure that no promotional content is included,
• follow health literacy and numeracy principles, and
• consider involving patients, patient representatives, or advocates in the development and 
review of the summary information to ensure that it truly meets their needs.
In particular, the document provides detailed information about the health literacy level to con-
sider in the summary, the readability specifying the size of the serif font, and the use of plain 
language, numeracy, and visuals. As the International Adult Literacy Survey identifies five levels 
of proficiency ranging from level 1 (lowest level) to level 5 (highest level), the document suggests 
that the text should be suitable for people with a low/medium average level of literacy (level 2 or 3). 
However, as readability scores are useful but not in themselves enough to ensure that a text is 
easy to understand, sponsors should consider, where feasible, testing the readability of an initial 
version of the study results’ summary with a small number of people who represent the target 
population. Depending on the nature of the study, this could be patients with a particular disease 
or it could be members of the public. For example, studies, which affect the general public such as 
vaccine studies, would benefit from input from members of the public rather than patients. Their 
feedback and suggestions can be crucial in developing a summary that lay people will understand.
Moreover, the Annex I of the recommendations offers the templates with user-friendly equiv-
alent headings, useful to prepare the summary, and even giving examples of wording more 
comprehensible for the target population.
Despite all attempts of increased awareness for the patient involvement in clinical research, 
rarely these initiatives pay attention to the pediatric population.
Children’s active participation in the decision-making process is necessary not only in the 
daily clinical practice, but also and especially in all the activities related to the development 
and use of drugs. In the last years, the idea that children’s preferences should always be taken 
into consideration is also agreed upon among parents. For this reason, healthcare profession-
als have to consider children and families’ active participation as a fundamental step to reach 
consensus and compliance to treatments and research.
Furthermore, in 2012, following a large consultation phase, the Pediatric Committee (PDCO) 
issued a “concept paper on the involvement of children and young people” in its activities, 
with the children’s best interests as primary consideration [7]. It has to be also highlighted 
that the setup of a child-friendly approach implies a collaborative and continuous action 
involving pediatricians and healthcare professionals, psychologists, families, and children.
Children and parents should be involved not only in the revision of clinical study protocols 
but also during the whole study development. Finally, it is necessary to recognize that a stan-
dard model of information is not valid for all age groups, above all for extreme groups.
2.3. Ethical considerations for clinical trials on medicinal products conducted with 
minors
The need to involve children actively in the decision-making process related to a clinical trial 
is clearly underlined also in the updating guideline “Ethical considerations for clinical trials 
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on medicinal products conducted with minors” [8]. The document was released by a group 
chaired by the European Commission with the aim to develop guidelines to implement the 
Directive 2001/20/EC relating to good clinical practice in the conduct of clinical trials on medic-
inal products for human use. The document, opened for consultation from June to August 
2016, provides recommendations on various ethical aspects of clinical trials performed in chil-
dren from birth up to the legal age of adulthood and will contribute to the protection of all 
children who are the subject of clinical trials.
Moreover, it underlines that “the investigator and protocol writer should ensure that there is 
involvement of children (suffering from the relevant condition) and families in the develop-
ment of informative material and where feasible, also in the design, analysis, and conduct 
of the trial.” Consequently, even if the pediatric population is not specifically cited by the 
EU Clinical Trials Regulation 536/2014 (Article 37) requiring sponsors to provide summary 
results of clinical trials in a format understandable to laypersons, children cannot be excluded 
by the advantages of this obligation.
By definition, children (minors) are unable to consent (in the legal sense), but they should be 
involved in the process of informed consent as much as possible, using appropriate age infor-
mation. In the ethical review, in fact, drawing on the pediatric expertise allows to balance the 
benefits, risks, and burden of research in minors. Moreover, the difference between minors 
and adults as research participants has implications on the design, conduct, and analysis of 
trials, which should also include pediatric expertise.
The Regulation EU 536/2014 provides a series of definitions in order to clarify some important 
concepts for the patient interaction and patient involvement and in particular the age groups. 
Defining the age range is necessary to have a guidance regarding the proper involvement of 
minors of different ages in the informed consent process. Subsets of the pediatric popula-
tion as defined in ICH E11 (ICH Harmonized Tripartite Guideline—Clinical Investigation 
of Medicinal Products in the Pediatric Population E11) [9] are partially adopted, and the age 
groups of 2–11 years and 12–17 years have been redefined as follows:
• preschoolers (2–5 years)
• schoolers (6–9 years)
• adolescents (from the age of 10 up to but not including above 18 years)
Regardless of the age and with an appropriate communication, the clinical trial regulation 
states that the child should be involved in the process of informed consent. The article 2 of 
clinical trial regulation defines the “Informed consent” as the document expressing the will 
of a subject to participate in a particular clinical trial; the subject, after having received infor-
mation on all the aspects of the clinical trial in which he/she will be involved, expresses his/
her decision in a free and voluntary way. In case of minors and of incapacitated subjects, it 
is intended as an authorization or agreement from their legally designated representative to 
include them in the clinical trial [5].
Moreover, the article 29(8) of the clinical trials regulation adds that also a minor should assent 
firsthand to participate in the clinical trial in cases in which he/she is capable of forming an 
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opinion and evaluating the information received, without prejudice to national law and in 
addition to the informed consent signed by the legally designated representative [5]. The 
ethical considerations document supports and highlights the legal value of the assent, sug-
gesting that assent should be understood as a legally required expression of the minor’s will 
to participate in a clinical trial, dependent on Member State law. According to this view, the 
assent should be considered in the same way as the consent of the parents/legally designated 
representative since it expresses with legal value the willingness of the child to participate in 
the clinical trial [8]. However, a minor who expresses the assent to join to a clinical trial cannot 
participate in it in absence of the informed consent signed by the parents/legally designated 
representative [8]. In addition, the consultation document introduces the term agreement, 
used in accordance with the term “assent,” to describe the expression of will to participate in 
a clinical study given by the minor. The document also recommends systematically requiring 
the agreement when it is not legally mandatory and explains that the modalities to obtain it, 
in contrast to the legally required assent, are not age dependent but are related only to the [8]. 
If the minor is considered not mature enough to express his/her will to participate in a con-
scious manner, the lack of agreement does not necessarily mean the child will not participate 
in the clinical trial. However, dissent should be taken into due account in line with Article 
32(1c) of the clinical trial regulation, when the minor, despite having proven his/her maturity, 
expresses his/her will not to participate [8].
Another important aspect discussed in the document is the importance to estimate to what 
extent a child is able to provide agreement. It is recommended to consider not only the chron-
ological age, but also and especially the developmental stage, intellectual capacities, and 
life/disease experiences of the minor. The evaluation should be made after a careful discus-
sion among the investigator, the parents/legally designated representative, and the child [8].
3. Patient and public involvement: the role of advocacy
Patient and public involvement (PPI) represents the active involvement of patients and/or indi-
viduals from the general population in scientific research with the aim to enhance quality and 
relevance of the research itself. Indeed, PPI strategies have shown in the last year to be key instru-
ments to improve the conduction, the communication, and the prioritization of the research.
The involvement of service users in research has risen internationally, with patients’ engage-
ment in all the aspects of health and social care research. PPI plans have been included suc-
cessfully in many clinical trial grant applications foreseeing patients’ engagement in all the 
phases of clinical research: initial stages, undertaking phase, analysis and write-up, dissemi-
nation, and implementation [10].
Jo Brett et al. [11] carried out a systematic search of electronic databases and health libraries 
to identify the impact of PPI on health and social care research. The authors pointed out that 
PPI can have positive impact on research, enhancing its quality and ensuring its appropriate-
ness and relevance. They also suggested that PPI strategies, to engage users in the initial stage 
of a medical research, are to be preferred since patients and lay people involvement in this 
step can shape the entire study and, users may have more freedom to influence the aims and 
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methods of the study. Moreover, they underlined that a clear definition of the roles of all the 
professionals and users involved through a precise planning and procedure, and training 
activities are important factors determining the success of the PPI.
Also, challenges to the development of plans for PPI have been described including issues 
regarding their purpose, difficulties in ensuring sufficient resources and in the recruitment 
of service users, the long-term commitment needed from service users, and the time and cost 
limits imposed on studies. Nonetheless, all the challenges mentioned above can be avoided by 
a precise planning of the PPI strategy, especially in the early stage of a proposed study [10, 11].
Among the current policies to encourage public involvement, strategies based on the concept 
of advocacy are spreading all over the world.
The World Health Organization (WHO) gave a definition of Advocacy for Health in the 
Health Promotion Glossary published in 1998 as “a combination of individual and social 
actions designed to gain political commitment, policy support, social acceptance, and system 
support for a particular health goal or program” [1].
According to this definition, advocacy stands for acting or doing something to influence pri-
vate and public policy choices’ in order to achieve an individual or community objective.
Advocacy is one of the three strategies underpinning health promotion as described in the 
WHO Health Promotion Glossary mentioned above, and many strategies have been described 
to reach this goal including the use of the mass media and multimedia, direct political lobby-
ing, and community mobilization through, for example, coalitions of interests around defined 
issues.
3.1. An innovative approach for the patient involvement: advisory groups in 
pediatric clinical research
When it comes to consider patient’s involvement in the pediatric field, more challenges have 
to be faced since the engagement of children requires appropriate means and language and it 
is also necessary to take into due account all the relevant legal and ethical aspects.
Despite these challenges, children have the right to be involved and informed, to know in 
advance which medicines they need and why and to get access to the resulting evidence-
based medicinal products. Their point of view has to be taken into due account in the design 
and planning of a clinical study, and they should be allowed to express their own views and 
granted the right to participate in the decision-making process concerning their own health.
An innovative approach for the patients’ involvement in pediatric clinical research is rep-
resented by the Young Persons Advisory Groups widespread through the world. A Young 
Persons Advisory Group (YPAG) is an organization composed of youths, patients, carers, and 
people interested in a health condition or in research, actively participating as partners, advising 
researchers and their teams in a full range of activities in various research projects and initiatives.
After educational and training activities, the youths become able to help researchers in trial 
design, prioritizing future researches, improving communication with the target population, 
and increase awareness on clinical research through the different means of communication.
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Many advisory groups have been founded, and all together they constitute the International 
Children’s Advisory Network (iCAN) [12], a worldwide consortium of children’s advisory 
groups or chapters working together to provide a voice for children and families in health, 
medicine, research, and innovation through synergy, communication, and collaboration. 
Within the consortium, various types of groups can be described, all working together for 
advocacy purposes in pediatric medicines:
• Kids and families impacting disease through science, (KIDS): Advisory groups of chil-
dren, adolescents, and families focused on understanding, communicating, and improving 
the process of medical innovation for children. KIDS groups have been created in Con-
necticut, Georgia, Missouri, Ohio, Illinois, Michigan, Texas, Florida, Barcelona, Australia, 
France, and recently in Italy and Albania.
• Young Persons Advisory Groups: a set-up in Great Britain (Liverpool, Birmingham, Lon-
don, Bristol, and Nottingham) as Generation R [13] with the aim to increase the input and 
influence of children and their families or carers into the development of clinical research.
• Kids Can (Vancouver): promoting a direct engagement of young people in research and 
the ScotCRN Young Persons Group (Scotland) aimed to support clinical research to im-
prove the safety and efficacy of children’s medicines and healthcare.
Advocating for children in healthcare globally is the main purpose of the network as well as 
taking into due account the children and families’ needs and willingness in health, research, 
medicine, and innovation in order to improve clinical research. iCAN’s chapters work both 
locally in partnership with their local children’s hospitals and communities and collaborate 
together network-wide to have a global impact.
Their slogan is: Together, we can improve the future of pediatric medicine!
The European chapters of iCAN (KIDS Barcelona, YPAG Birmingham, YPAG Bristol, 
KIDS France, YPAG Liverpool, YPAG London, YPAG Nottingham, YPAG Scotland) have 
recently established a European YPAGs’ network, or eYPAGnet [14], under the coordina-
tion of Hospital Sant Joan de Déu (Barcelona) as part of the iCAN umbrella organization. 
This network arose from the need, recognized by the Enpr-EMA (European Network of 
Pediatric Research at the European Medicines Agency), to promote cooperation among 
European groups with the mission to improve the capacity of collaboration with the dif-
ferent actors who participate in the research and development process of innovative drugs 
in Europe.
Enpr-EMA has promoted several actions with the aim to foster engagement of young people 
and families in clinical research. A survey on the involvement of young people and family mem-
bers in Enpr-EMA pediatric research networks was launched in August 2012 and highlighted 
that only three out of the 39 networks participating to the survey had developed strategies or 
guidelines for the involvement of young people and families. A second survey was conducted 
in November 2016 to investigate the point of view of the Pediatric Committee (PDCO) members 
in relation to the involvement of young people and families in the activities of the Committee. 
Moreover, a working group on young patient advisory groups has been established in order to 
develop harmonized procedures for a more European-oriented approach of YPAGs.
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The working group has launched two surveys to investigate the characteristics of the exist-
ing YPAGs with the final aim to create a European network of young advisory groups and to 
define the best practices to address issues in the framework of the EU multilanguage YPAGs. 
Within these initiatives, eYPAGnet has been created and admitted, during 2017 annual meet-
ing, as member of Enpr-EMA of category 4.
Among the main scopes of eYPAGnet, there are development of clinical research initiatives and 
empowerment training programs for children on a European level and the promotion of new chap-
ters’ set-up. Indeed, since June 2017, two new chapters, KIDS Bari and KIDS Albania have been 
created in Europe and are coordinated by Consorzio per Valutazioni Biologiche e Farmacologiche 
(CVBF) and the TEDDY Network (European Network of Excellence for Pediatric Clinical Research).
CVBF is a not-for-profit organization aimed to perform research in life science at European 
level with a special focus on drug development for small populations (pediatric and rare 
diseases). It provides scientific, economic, and regulatory consultancy in pediatric clinical 
research and a research management support in national and international research projects. 
Particular interest is given to promote educational activities supporting the consortium’s 
areas of expertise and to favor knowledge and access to the results of biomedical research 
and accelerate their use by patients. The consortium has developed a considerable expertise 
in communication and dissemination field, leading and managing these activities in several 
EU-funded projects (GAPP, DEEP, CloSed, and InNerMeD).
The TEDDY Network was born as an EC-FP6-funded Network of Excellence (NoE) and now 
is an independent multidisciplinary and multinational network including 50 members in 20 
EU and non-EU countries aimed to favor the integration of the pediatric pharmacological 
research activities, the implementation of adequate health policies, and a social awareness 
on the importance of the pediatric medicines across Europe covering different specialty areas 
(hematology, oncology, infectious diseases, respiratory diseases, intensive care, pain, endocri-
nology, rare diseases, neonatology, etc.).
TEDDY is a category 1 network member of Enpr-EMA and collaborates with existing pedi-
atric networks and research organizations with the goal to promote and foster scientific and 
technological excellence in the pediatric research in Europe.
3.2. Advisory group contribution in pediatric clinical research
Existing advisory groups and initiatives have shown to be an effective form of patient and 
public involvement in the pediatric field providing fresh perspectives on pediatric clinical 
research and promoting changes of attitudes about the involvement of young people in all the 
aspects of medicines research.
The activities carried out by all the advisory groups across the world are aimed at contribut-
ing to raise awareness of the importance of patient and public involvement in the develop-
ment of research trial.
The education and, in particular, the peer education is a fundamental aspect of the advocacy 
strategy. The peer education is an educational approach, recommended by modern development 
psychology, based on teaching and sharing information, values, and behavior relating to health 
promotion among lay people. Through this approach, advocacy groups aim to provide children 
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and families with resources and opportunities to express their feedback and inputs about studies 
and products intended for children.
iCAN is a free resource available to any organization, company, or group, which seeks the input 
of children and families in their projects. iCAN chapters utilize online-based surveys, focus 
groups, forums, and more to engage all of the youth advisory groups in their network to provide 
specific feedback about clinical trials or any other process of medical innovation for children.
Moreover, many groups work on research projects on their own and participate in science 
conferences to disseminate their results and to highlight the importance of their involvement 
in research. Just to mention some examples of projects carried out by iCAN chapters, Kids 
Can developed a mobile application “Mobile Kids” [15] to encourage physical activity in kids 
aged between 8 and 13 years with the use of mobile technology.
Kids Can and Kids Connecticut participated in the development of guidelines aimed to stan-
dardize reporting of clinical trial protocol (SPIRIT-C) [16] and trial reports (CONSORT-C) [17]
across pediatric studies.
Members of US, Canada, and UK young patients’ advisory groups provided their contribu-
tion responding to a survey launched by the Global Alliance for Pediatric Therapeutics Assent 
Project [18], a project aimed to evaluate current practices, challenges, and unmet needs associ-
ated with the achievement of pediatric assent for clinical trials.
KIDS Barcelona group provided recommendations [19] to be taken into account by the sponsor 
of a clinical trial and ethics committee of the research center to make the assent form more under-
standable for children. The recommendations are collected in a guideline, available in Spanish 
and English, approved by iCAN and EUPATI and included in the guidelines for the design of a 
pediatric clinical trial by Agencia Española de Medicamentos y Productos Sanitarios (AEMPS). 
Moreover, the Spanish group has developed a series of eight different funny comics [20] to 
explain several matters of the clinical research using a language more familiar for the children.
Furthermore, YPAGs have given their useful contribution in the revision of informed consent/
assent template prepared by Enpr-EMA within the activities of the working group 4 on eth-
ics providing their thoughts and ideas to make the template more understandable by a wide 
range of ages.
By many activities and initiatives performed, the young advisor groups spread all over the 
world are able to help the professionals involved in the clinical trials to overcome some tough 
issues of the clinical research. For example, they could help to open and complete on time 
the trials or could improve the recruitment of patients to the agreed target and the retention 
of patients to completion. In general, through the YPAGs, the clinicians involved in the trials 
could meet the needs of the patients, designing the study according to their necessities.
4. Patient-centered approach to improve pediatric clinical research: 
some good practices
It is universally established that written communication, combined with verbal interaction, 
may enhance children’s understanding of their participation in a clinical research [21] as well 
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as the contents and styles of documents addressed to children are elements that largely influ-
ence their understanding of written documents.
As an example, it has been demonstrated that the use of pictures, following appropriate rec-
ommendations, improves the quality of communication, especially for patients with very low 
literacy skills. However, available data and publications show that ad hoc informative strate-
gies for empowering minors in clinical trials are rarely produced. In addition, the difficulty 
increases in multicenter trials, involving countries with different cultural and educational 
backgrounds.
This is the assumption at the basis of the development of age-tailored information booklets, 
assent forms, and videos prepared in the framework of the DEferiprone Evaluation in Pediatrics 
[22] (DEEP) and GAbapentin in Pediatric Pain [23] (GAPP) projects, two EC-FP7 funded proj-
ects coordinated by Consorzio per Valutazioni Biologiche e Farmacologiche (CVBF).
All the materials have been developed with a language and a wording appropriate to age, 
psychological and intellectual maturity, taking into account the cultural and linguistic dif-
ferences, in a collaborative effort among pharmacologists, pediatricians, child psychologists, 
and illustrators.
In the framework of the GAPP project, aimed to confirm the efficacy and safety of gabapentin 
in pediatric patients affected by chronic pain with a neuropathic component, three booklets 
and two videos (Figure 2) have been created to inform the child participant on the study 
objectives and procedures. Two assent forms have been released to obtain his/her consent to 
Figure 2. GAPP projects’ video: in the framework of the GAPP project activities, two videos have been developed to 
inform the child participant on the study objectives and procedures according to two age ranges (for children on the top 
and for teenagers on the bottom).
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Figure 3. DEEP project booklets: the pages extracted from the three booklets, developed for three different age ranges 
(age range 0–6, 6–10, and 10–17, respectively, in the top, middle, and bottom pages), explain how the clinical trial will 
be carried out.
participate in the study. A patient diary has also been developed to register specific daily data 
on the use of the Investigational Medicinal Products (IMPs), rescue and concomitant medica-
tion, pain scores, and adverse effects when the patient is at home. It also contains instructions 
for the use of the IMP, troubleshooting, and contact details of the study’s medical staff.
For the young participants of the DEEP project, aimed to marketing a new formulation of 
deferiprone for the treatment of iron overload in pediatric patients affected by congenital 
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anemia, three different booklets (Figure 3) explaining clinical trial aims and procedures 
and what they are going to experience, and two different assent forms were prepared. 
For both projects, all these informative materials are available in all the languages of the 
project.
Informative videos (a spoonful of info helps the medicine go down) [24], specifically addressed 
to children between 4 and 7 years old explaining some main concepts on drugs and their 
use, have also been developed by the TEDDY Network of Excellence for Pediatric Clinical 
Research within the empowerment activities addressed to young patients in the healthcare 
field.
5. Conclusions
There is a need to change attitudes in order to make the patients’ empowerment a priority 
in the clinical research field. Patients have to take an active role in activities or decisions that 
will have consequences for the patient community, because of their specific knowledge and 
relevant experience as patients. Children’s active participation in the decision-making pro-
cess is needed not only in the daily clinical practice, but also in all the activities related to the 
development and use of drugs. Minor shall take part in the informed consent procedure in a 
way adapted to his/her age and mental maturity.
Patients/families need to be considered as “co-managers” of their condition and participate in 
decisions related to their healthcare according to their capacity. Moreover, patients (individu-
ally and) collectively have to play a role in improving healthcare services for all patients by 
contributing with their specific experiences as learning and educational tools to inform and 
(re-) design of services.
However, the involvement must be planned, appropriately resourced, carried out, and evalu-
ated as to its outcomes, impact, and the process itself, according to the values and purposes 
of all participants. Engaging children early in the research process and educating the world 
about the importance of participating in clinical research could increase the level of participa-
tion in pediatric clinical trials, thus reducing the patients’ retention and fostering treatment 
compliance. Moreover, a patient-centered approach can improve the capacity of collaboration 
with the different agents, who participate in the research process and in the development of 
innovative drugs.
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